| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2087 | 2017 |
| PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ... New England Journal of Medicine 379 (4), 341-351, 2018 | 1284 | 2018 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 899 | 2019 |
| Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... The Lancet 397 (10274), 592-604, 2021 | 571 | 2021 |
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... The lancet oncology 17 (4), 452-463, 2016 | 505 | 2016 |
| Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial MR Migden, NI Khushalani, ALS Chang, KD Lewis, CD Schmults, ... The lancet oncology 21 (2), 294-305, 2020 | 385 | 2020 |
| Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial AJ Stratigos, A Sekulic, K Peris, O Bechter, S Prey, M Kaatz, KD Lewis, ... The Lancet Oncology 22 (6), 848-857, 2021 | 211 | 2021 |
| Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia DW Volk, T Matsubara, S Li, EJ Sengupta, D Georgiev, Y Minabe, ... American Journal of Psychiatry 169 (10), 1082-1091, 2012 | 164 | 2012 |
| Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance GD Hoftman, DW Volk, HH Bazmi, S Li, AR Sampson, DA Lewis Schizophrenia bulletin 41 (1), 180-191, 2015 | 153 | 2015 |
| Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing D Rischin, MR Migden, AM Lim, CD Schmults, NI Khushalani, ... Journal for immunotherapy of cancer 8 (1), 2020 | 150 | 2020 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial M Gogishvili, T Melkadze, T Makharadze, D Giorgadze, M Dvorkin, ... Nature Medicine 28 (11), 2374-2380, 2022 | 129 | 2022 |
| Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial TU Marron, MI Fiel, P Hamon, N Fiaschi, E Kim, SC Ward, Z Zhao, J Kim, ... The Lancet Gastroenterology & Hepatology 7 (3), 219-229, 2022 | 103 | 2022 |
| Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib S George, P Reichardt, T Lechner, S Li, DP Cohen, GD Demetri Annals of oncology 23 (12), 3180-3187, 2012 | 100 | 2012 |
| Molecular correlates differentiate response to atezolizumab (atezo)+ bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic … BI Rini, M Huseni, MB Atkins, DF McDermott, TB Powles, B Escudier, ... Annals of Oncology 29, viii724-viii725, 2018 | 84 | 2018 |
| In the world or in the head: External and internal implicit theories of creativity SBF Paletz, K Peng, S Li Creativity Research Journal 23 (2), 83-98, 2011 | 71 | 2011 |
| Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis D Rischin, NI Khushalani, CD Schmults, A Guminski, ALS Chang, ... Journal for immunotherapy of cancer 9 (8), 2021 | 69 | 2021 |
| A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer … DP Petrylak, K Fizazi, CN Sternberg, N Budnik, R De Wit, PJ Wiechno, ... Annals of Oncology 23, ixe15, 2012 | 54 | 2012 |
| Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. D Rischin, NI Khushalani, CD Schmults, AD Guminski, ALS Chang, ... Journal of Clinical Oncology 38 (15_suppl), 10018-10018, 2020 | 53 | 2020 |
| IMvigor210 Study Group Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm … AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... Lancet 389 (10064), 67-76, 2017 | 53 | 2017 |
| Increased expression of Kalirin-9 in the auditory cortex of schizophrenia subjects: its role in dendritic pathology AJ Deo, ME Cahill, S Li, I Goldszer, R Henteleff, JE VanLeeuwen, ... Neurobiology of disease 45 (2), 796-803, 2012 | 52 | 2012 |
Armando RastelliProfessor of Semiconductor Physics, Johannes Kepler University LinzVerified email at jku.at
